Pharmaceutical manufacturing is among the most heavily regulated sectors in Iraq, reflecting public health implications and Iraq’s emphasis on domestic pharmaceutical capability. The framework engages the Ministry of Health and Environment through the Drug Regulatory Authority, KIMADIA for State procurement, and international standards bodies. The regulatory pathway is substantial but workable, and the market opportunity reflects the regulatory effort.
Drug Regulatory Authority
The Iraqi Drug Regulatory Authority under the Ministry of Health is the principal pharmaceutical regulator. Functions include facility licensing for pharmaceutical manufacturers, product registration for medicinal products, GMP inspection, controlled substance management, and pharmacovigilance. The Authority coordinates with KIMADIA on State procurement matters.
Facility Licensing
Pharmaceutical manufacturing facilities require specific licensing addressing facility design appropriate for pharmaceutical production (cleanrooms, environmental controls, separation of incompatible operations), equipment qualification and process validation, quality systems including documentation and change control, personnel qualifications and training, raw material control and supplier qualification, and finished product testing and release. The licence is the substantive approval to manufacture pharmaceuticals.
GMP Compliance
Pharmaceutical manufacturing must comply with Good Manufacturing Practice (GMP) standards aligned with the WHO GMP framework. GMP covers:
- Quality management systems with documented procedures
- Personnel qualification and continuing training
- Facility design and environmental control
- Equipment qualification and validation
- Raw materials and packaging materials control
- Production controls and in-process testing
- Quality control laboratory operations
- Storage and distribution control
- Complaints handling and recall procedures
- Continuous improvement and deviation management
GMP is the principal operational discipline of pharmaceutical manufacturing.
Product Registration
Each pharmaceutical product marketed in Iraq requires registration with the Drug Regulatory Authority. Registration requires comprehensive documentation including product formulation and manufacturing process, quality data including specifications and analytical methods, stability data, safety and efficacy data, labelling and packaging information, and pricing information. Registration is product-specific and renewable periodically.
Generic and Branded Products
Iraqi pharmaceutical manufacturing covers both generic products and branded products. Generic registration is generally faster and more procedural than originator registration, but bioequivalence data is increasingly expected at international standards.
Controlled Substances
Manufacturers of controlled substances (narcotics, psychotropics, and certain restricted categories) require additional licensing covering security arrangements, enhanced record-keeping, distribution control to prevent diversion, and coordination with international controlled substances frameworks.
KIMADIA and State Procurement
KIMADIA is the principal procurer of pharmaceuticals for the Iraqi public health system. Tenders, supplier qualification, and supply arrangements are commercially significant for Iraqi pharmaceutical manufacturers. Participation engages tender processes and performance commitments.
Pharmacovigilance
Manufacturers have ongoing obligations covering adverse event reporting, post-marketing surveillance, periodic safety updates, and response to safety signals. Pharmacovigilance is both regulatory requirement and substantive patient safety commitment.
How We Can Help
Etihad advises pharmaceutical manufacturers across the full regulatory lifecycle, facility licensing, GMP compliance, product registration, controlled substances licensing, KIMADIA engagement, and ongoing regulatory matters.